Meet Stratis

Prior to 2011, the founding partners were working together at a boutique pharma strategy company in NYC – sharing an office, a white board, and a dream.

SkyLaunch was founded in 2011 specifically to deliver Market Access Impact Analytics and Launch Models to small-to-midsized pharma companies. We primarily worked with market access teams – building launch forecasts based on longitudinal payer-level access settings.

By 2014, the combination of an evolving data landscape and the inherent accuracy of payer-level forecasts meant that we were able to deliver related insights and analytics across the product lifecycle so we re-branded to Stratis Group.

By 2015, our work and expertise in rare diseases had reached an aggressive volume, and we had learned how unique and yet under-supported the space is. The industry was struggling to justify investment in the space because the data to quantify returns was terrible.

We founded BluePrint Orphan in 2016 to specifically focus on removing the barriers to investment by improving the "knowns" in the rare and orphan space.

Today, while we operate three unique brands, we’re all one family with complementing skill sets.  Our employees at each company typically start with an existing skillset in pharma, or advanced degrees in Epi with experience or an interest in pre/clinical development & commercialization strategy.